BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32109140)

  • 1. The Relationship Between Total Lesion Activity on
    Filippi L; Basile P; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
    Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
    Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim and end-treatment
    García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
    Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
    Naito M; Ukai R; Hashimoto K
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
    Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
    Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of
    Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
    Kwee SA; Lim J; Coel MN
    Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of
    Filippi L; Spinelli GP; Chiaravalloti A; Schillaci O; Equitani F; Bagni O
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33266047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
    Maines F; Caffo O; Donner D; Sperduti I; Bria E; Veccia A; Chierichetti F; Tortora G; Galligioni E
    Future Oncol; 2016 Feb; 12(3):333-42. PubMed ID: 26768648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
    Iizuka J
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.